Locus Biosciences
Locus Biosciences (Locus) is a clinical-stage pharmaceutical company based in Morrisville (Research Triangle Park), North Carolina, founded in 2015 as an NCSU spin‑out.
≈ 2 min read
Locus Biosciences. encyclopegia.org, snapshot enwiki-001359719557. /a/locus-biosciences
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Locus Biosciences (Locus) is a clinical-stage pharmaceutical company based in Morrisville (Research Triangle Park), North Carolina, founded in 20151 as an NCSU spin‑out. It develops CRISPR-Cas3–enhanced bacteriophage therapies (“crPhage”) targeting drug-resistant bacterial infections.
Its lead candidate, LBP‑EC01, delivered by a phage cocktail that lyses bacteria while irreversibly degrading their DNA, has completed a Phase 1b randomized, placebo‑controlled trial demonstrating safety and tolerability and has progressed to the Phase 2 ELIMINATE trial—Part 1 delivered positive open-label results and Part 2 is now underway with BARDA funding. Locus also has programs in development targeting Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus, and broader microbiome‑related indications such as inflammatory bowel disease.
Clinical development
The company enrolled its first patient in a Phase 1b clinical trial for LBP-EC01 in 2020 and successfully completed the trial in 2021. Locus subsequently announced positive results from Part 1 of a two-part Phase 2 clinical trial of LBP-EC01, which was published in The Lancet Infectious Diseases. These positive results resulted in $23.9 million additional funding from BARDA to support Part 2 of the Phase 2 clinical trial.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1359719557 under CC BY-SA 4.0; modifications have been made.
References
- ↩Wikipedia “Locus Biosciences” date of foundation (×1) · confidence 0.95 revision URL